Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diphtheria-tetanus-pertussis-inactivated poliomyelitis and Haemophilus influenzae type b combination vaccine
- Development stage
- Approved
- Lead developer
- Beijing Minhai Biological
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
This is a pentavalent combination vaccine developed by Beijing Minhai Biotechnology for the prevention of five infectious diseases in infants and children: diphtheria, tetanus, pertussis, poliomyelitis, and invasive *Haemophilus influenzae* type b (Hib) infections. The vaccine consists of adsorbed acellular pertussis antigens, diphtheria and tetanus toxoids, inactivated poliovirus (IPV), and Hib capsular polysaccharide conjugated to a carrier protein. By combining these antigens into a single injection, the vaccine aims to reduce the number of required immunizations, thereby improving compliance and coverage. It is currently undergoing Phase I clinical evaluation in China to assess its safety and immunogenicity in healthy participants aged 3 months to 6 years.
- Other names
- DTaP-IPV-Hib vaccinepentavalent vaccine (DTaP-IPV-Hib)adsorbed acellular diphtheria-tetanus-pertussis-inactivated poliomyelitis and Haemophilus influenzae type b combination vaccine
02
Targets
Poliovirus type 1 capsid proteinPRN (Pertactin)WPV3 (Poliovirus type 3 capsid protein)TT (Tetanus toxoid)
Beyond the preview
Go deeper on diphtheria-tetanus-pertussis-inactivated poliomyelitis and Haemophilus influenzae type b combination vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diphtheria-tetanus-pertussis-inactivated poliomyelitis and Haemophilus influenzae type b combination vaccine.